Suppr超能文献

辅助全身抗菌药物治疗慢性牙周炎:系统评价和网络荟萃分析。

Adjunctive systemic antimicrobials in the treatment of chronic periodontitis: A systematic review and network meta-analysis.

机构信息

Private Practice, San Benedetto del Tronto, Marche, Italy.

Private Practice, Rieti, Lazio, Italy.

出版信息

J Periodontal Res. 2021 Apr;56(2):236-248. doi: 10.1111/jre.12821. Epub 2020 Dec 12.

Abstract

The aim of this systematic review and network meta-analysis was to assess the efficacy of antimicrobials adjunctive to scaling and root planing (SRP) in the treatment of chronic periodontitis. The study was conducted according to the PRISMA statement. The protocol (CRD42020178621) was registered on the International Prospective Register of Systematic Reviews (PROSPERO). The MEDLINE, EMBASE, and CENTRAL databases were searched up to March 2020; furthermore, a manual search of relevant periodontal journals was conducted. Mean differences (MD) and standard deviations were calculated for clinical attachment level (CAL) gain and probing depth (PD) reduction at 6 and 12 months. A network meta-analysis was performed to assess direct and indirect comparisons and to establish a ranking of treatments. A total of 21 randomized clinical trials (RCTs) were included in the systematic review. Network meta-analysis showed that SRP + amoxicillin (AMX) + metronidazole (MTZ), as compared to SRP, reached the highest PD reduction at 6 [MD = 0.47; 95% CI (0.3; 0.64)] and 12 months [MD = 0.51; 95% CI (0.25; 0.78)], and CAL gain at 6 [MD = 0.54; 95% CI (0.27; 0.8)] and 12 months [MD = 0.37; 95% CI (0.05; 0.69)]. Network meta-analysis indicated that AMX + MTZ adjunctive to SRP provided the best improvement in clinical parameters, followed by SRP + MTZ.

摘要

本系统评价和网络荟萃分析的目的是评估在慢性牙周炎治疗中,除了牙周洁治(SRP)之外,使用抗生素辅助治疗的疗效。研究按照 PRISMA 声明进行。方案(CRD42020178621)已在国际前瞻性系统评价注册库(PROSPERO)注册。检索了 MEDLINE、EMBASE 和 CENTRAL 数据库,检索时间截至 2020 年 3 月;此外,还对相关牙周期刊进行了手动检索。6 个月和 12 个月时,计算了临床附着水平(CAL)增加和探诊深度(PD)减少的均值差值(MD)和标准差。进行了网络荟萃分析,以评估直接和间接比较,并确定治疗方法的排名。本系统评价共纳入 21 项随机临床试验(RCT)。网络荟萃分析显示,与 SRP 相比,SRP+阿莫西林(AMX)+甲硝唑(MTZ)在 6 个月时[MD=0.47;95%CI(0.30;0.64)]和 12 个月时[MD=0.51;95%CI(0.25;0.78)]达到了最大的 PD 降低,在 6 个月时[MD=0.54;95%CI(0.27;0.8)]和 12 个月时[MD=0.37;95%CI(0.05;0.69)]达到了最大的 CAL 增加。网络荟萃分析表明,在 SRP 的基础上加用 AMX+MTZ 辅助治疗在临床参数改善方面效果最佳,其次是 SRP+MTZ。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验